News from bergenbio asa A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 11, 2020, 08:19 ET BerGenBio Presents Phase II Bemcentinib Combination Study in NSCLC at Annual SITC Meeting

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical...


Oct 23, 2020, 01:15 ET BerGenBio Virtual R&D Day - 06 November 2020

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical...


Sep 01, 2020, 01:19 ET BerGenBio to Present at Upcoming Investor Conferences

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical...


Aug 18, 2020, 01:29 ET BerGenBio ASA: Results for the Second Quarter and First Half of 2020

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need...


Aug 10, 2020, 01:17 ET BERGENBIO ASA: Invitation to second quarter 2020 results webcast presentation

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, will ...


Jul 28, 2020, 11:53 ET Update On Bemcentinib's Involvement in Potential Treatment of COVID-19 Pandemic

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, notes ...


Jul 20, 2020, 01:17 ET Bergenbio Announces First Patient Dosed in Recurrent Glioblastoma Investigator Sponsored Phase I/II Study Assessing Selective AXL Inhibitor Bemcentinib

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical...


Jul 07, 2020, 01:25 ET BerGenBio to Present at Digital Novel Coronavirus Investment Forum

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical...


Jun 25, 2020, 13:28 ET BerGenBio Announces Positive Interim Clinical and Translational Data from Phase II Trial of Bemcentinib in Combination with Keytruda® in Checkpoint Inhibitor Refractory NSCLC Patients

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical...


Jun 24, 2020, 01:24 ET BerGenBio Announces Change to Presentation Time at Next Gen Immuno-Oncology Congress

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical...


Jun 15, 2020, 01:45 ET BerGenBio to Present Top Line Translational Phase II Data With Bemcentinib in Combination With Keytruda® in NSCLC Patients At Next Gen Immuno-Oncology Congress

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical...


Jun 02, 2020, 01:12 ET Bergenbio Confirms First Covid-19 Patient Dosed With Bemcentinib in Accord Trial

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical...


May 19, 2020, 01:20 ET BerGenBio ASA: Results for the First Quarter 2020

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need,...


May 13, 2020, 01:20 ET BerGenBio ASA: Invitation to First Quarter 2020 Results Webcast Presentation

BerGenBio ASA (OSE: BGBIO), will announce its results for the first quarter 2020 on Tuesday 19 May 2020. A webcast presentation by BerGenBio's senior ...


May 05, 2020, 01:27 ET BerGenBio Raises Nok500m (€45.4m) via an Over Subscribed Private Placement

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, is...


Apr 28, 2020, 18:01 ET BerGenBio's Bemcentinib Selected to Be Fast-tracked As Potential Treatment for COVID-19 Through New National UK Government Clinical Trial Initiative

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need,...


Feb 11, 2020, 01:09 ET BerGenBio ASA: Results For The Fourth Quarter and Full Year 2019

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer...


Jan 29, 2020, 19:12 ET BerGenBio ASA - Private Placement Successfully Placed

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG...


Jan 15, 2020, 11:30 ET BerGenBio Meets Efficacy Endpoint For First Stage Of Phase II Trial With AXL Inhibitor Bemcentinib in Combination With Keytruda® in NSCLC Patients Progressing on Immune Checkpoint Inhibitors

BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer...


Dec 09, 2019, 01:30 ET BerGenBio Presents Preliminary Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC in Elderly AML Patients at ASH 2019

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer...


Nov 19, 2019, 01:23 ET BerGenBio ASA: Results for the Third Quarter 2019

FDA granted Fast Track Designation for 2L Acute Myeloid Leukaemia (AML) High Impact oral presentation of 2L NSCLC clinical data at SITC Met primary...


Nov 08, 2019, 07:27 ET BerGenBio Presents Updated Phase 2 NSCLC Clinical and Translational Data for Bemcentinib in Combination With KEYTRUDA®

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer...


Nov 07, 2019, 06:43 ET BerGenBio to Present Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC Trial in Elderly AML Patients at ASH 2019

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer...


Nov 07, 2019, 01:32 ET BerGenBio ASA: Invitation to Third Quarter 2019 Results Presentation and Webcast

BerGenBio ASA (OSE:BGBIO), will announce its results for the third quarter on Tuesday 19 November 2019. A presentation by BerGenBio's senior...


Nov 06, 2019, 01:38 ET BerGenbio's Bemcentinib Meets Primary Endpoint in First Cohort of Phase 2 NSCLC Study in Combination With Keytruda®

BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer...